Tamarind Bio
Tamarind Bio provides scientists a no-code platform to design and optimize proteins, antibodies, enzymes, and peptides at large scale. It exposes web interfaces and APIs that run public molecular-design models (AlphaFold, RFdiffusion, ProteinMPNN and 200+ models) using AI and physics-based computation to generate, score, and optimize sequences in high-throughput workflows. The product is a B2B SaaS platform for life-science companies and research organizations and supports batch parallelization for hundreds of thousands of inputs. Core capabilities include de novo binder design, antigen stabilization and solubility optimization, affinity improvement, and developability scoring for antibodies. The platform emphasizes secure data handling, user-friendly workflows, and API integrations for internal protein-engineering pipelines.
Tamarind Bio
Tamarind Bio provides scientists a no-code platform to design and optimize proteins, antibodies, enzymes, and peptides at large scale. It exposes web interfaces and APIs that run public molecular-design models (AlphaFold, RFdiffusion, ProteinMPNN and 200+ models) using AI and physics-based computation to generate, score, and optimize sequences in high-throughput workflows. The product is a B2B SaaS platform for life-science companies and research organizations and supports batch parallelization for hundreds of thousands of inputs. Core capabilities include de novo binder design, antigen stabilization and solubility optimization, affinity improvement, and developability scoring for antibodies. The platform emphasizes secure data handling, user-friendly workflows, and API integrations for internal protein-engineering pipelines.
TL;DR
What they do: No-code SaaS platform and API for large-scale computational protein design (AlphaFold, RFdiffusion, ProteinMPNN, GROMACS and 200+ models).
Customers: Life-science companies, biotechs, pharmaceutical researchers, and academic labs.
Funding: $13.6M total (includes $12M Series A led by Dimension Capital); prior Seed with Y Combinator participation.
Founded / HQ: Founded 2023; headquartered in San Francisco, California.
Company Overview
Problem Domain
Computational protein design, antibody/peptide/enzyme engineering, structure prediction and high-throughput molecular-design workflows.
Founded
2023
Industry
Biotechnology
Tech Stack
Funding Track Record
Crunchbase lists a Seed round on Apr 3, 2024 with Y Combinator and other investors.
$12,000,000
Company announced a $13.6M fundraise including a $12M Series A led by Dimension Capital.
Investor Signal
“Participation from Y Combinator; Series A led by Dimension Capital with participation from other institutional investors (e.g., Eight Capital, Treeo VC listed as investors).”